GH * Stock Overview
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 1/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Guardant Health, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$285.30 |
52 Week High | US$662.50 |
52 Week Low | US$293.83 |
Beta | 0.90 |
1 Month Change | -7.67% |
3 Month Change | n/a |
1 Year Change | -35.74% |
3 Year Change | -90.58% |
5 Year Change | n/a |
Change since IPO | -81.86% |
Recent News & Updates
Recent updates
Shareholder Returns
GH * | MX Healthcare | MX Market | |
---|---|---|---|
7D | -2.9% | -3.6% | -1.0% |
1Y | -35.7% | 2.4% | 1.4% |
Return vs Industry: GH * underperformed the MX Healthcare industry which returned 2.4% over the past year.
Return vs Market: GH * underperformed the MX Market which returned 1.4% over the past year.
Price Volatility
GH * volatility | |
---|---|
GH * Average Weekly Movement | n/a |
Healthcare Industry Average Movement | 5.6% |
Market Average Movement | 3.8% |
10% most volatile stocks in MX Market | 6.1% |
10% least volatile stocks in MX Market | 1.7% |
Stable Share Price: GH *'s share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine GH *'s volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2011 | 1,774 | Helmy Eltoukhy | guardanthealth.com |
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection.
Guardant Health, Inc. Fundamentals Summary
GH * fundamental statistics | |
---|---|
Market cap | Mex$36.68b |
Earnings (TTM) | -Mex$8.22b |
Revenue (TTM) | Mex$9.66b |
3.8x
P/S Ratio-4.5x
P/E RatioIs GH * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
GH * income statement (TTM) | |
---|---|
Revenue | US$563.95m |
Cost of Revenue | US$227.05m |
Gross Profit | US$336.90m |
Other Expenses | US$816.35m |
Earnings | -US$479.45m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 09, 2024
Earnings per share (EPS) | -3.94 |
Gross Margin | 59.74% |
Net Profit Margin | -85.02% |
Debt/Equity Ratio | 718.4% |
How did GH * perform over the long term?
See historical performance and comparison